149 related articles for article (PubMed ID: 34972538)
1. [Administrative delays of temporary recommendation for use: Impact on access to innovation in melanoma].
Auger C; Guillot B; Monard A; Albin N
Bull Cancer; 2022 Jan; 109(1):28-37. PubMed ID: 34972538
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
[No Abstract] [Full Text] [Related]
3. Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
Stellato D; Gerbasi ME; Ndife B; Ghate SR; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Manag Care Spec Pharm; 2019 Nov; 25(11):1227-1237. PubMed ID: 31663466
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Therapy of Melanoma.
Tarhini AA
Hematol Oncol Clin North Am; 2021 Feb; 35(1):73-84. PubMed ID: 33759774
[TBL] [Abstract][Full Text] [Related]
5. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
[TBL] [Abstract][Full Text] [Related]
6. [Stage III melanoma: Sentinel node biopsy, completion lymph node dissection and prospects of adjuvant therapy. A French national survey on current and envisaged practices].
Orion C; Dinulescu M; Dalac-Rat S; Giacchero D; Jouary T; Lebbé C; Leccia MT; Maubec E; Meyer N; Mortier L; Dupuy A;
Ann Dermatol Venereol; 2020 Jan; 147(1):9-17. PubMed ID: 31761496
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma.
Sharma R; Koruth R; Kanters S; Druyts E; Tarhini A
J Comp Eff Res; 2019 Dec; 8(16):1349-1363. PubMed ID: 31778073
[No Abstract] [Full Text] [Related]
8. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D
Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005
[TBL] [Abstract][Full Text] [Related]
9. The future of melanoma therapy: developing new drugs and improving the use of old ones.
Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
[No Abstract] [Full Text] [Related]
10. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
[TBL] [Abstract][Full Text] [Related]
12. Two cases of dabrafenib and trametinib therapy-failed advanced melanoma successfully controlled by nivolumab monotherapy.
Sato Y; Fujimura T; Kambayashi Y; Tanita K; Tono H; Hashimoto A; Aiba S
J Dermatol; 2018 Sep; 45(9):1105-1108. PubMed ID: 29923635
[TBL] [Abstract][Full Text] [Related]
13. Custo-utilidade de terapias-alvo comparadas à dacarbazina para o tratamento de primeira linha do melanoma avançado não-cirúrgico e metastático no Sistema Único de Saúde do Brazil.
Guerra RL; Corrêa FM; Fernandes RRA; Zimmerman IR
Value Health Reg Issues; 2019 Dec; 20():103-109. PubMed ID: 31174179
[TBL] [Abstract][Full Text] [Related]
14. Provocative questions, better biomarkers, and the prospect of triple therapy: a conversation with NYU's Jeffrey S. Weber, MD, PhD.
Weber JS; Caffrey MK
Am J Manag Care; 2018 Feb; 24(2 Spec No.):SP53-SP54. PubMed ID: 29689139
[No Abstract] [Full Text] [Related]
15. The new paradigm of systemic therapies for metastatic melanoma.
Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
[TBL] [Abstract][Full Text] [Related]
16. The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
Donia M; Ellebaek E; Øllegaard TH; Duval L; Aaby JB; Hoejberg L; Køhler UH; Schmidt H; Bastholt L; Svane IM
Eur J Cancer; 2019 Feb; 108():25-32. PubMed ID: 30605822
[TBL] [Abstract][Full Text] [Related]
17. GSK drug combination approved for advanced melanoma.
Inman S
Am J Manag Care; 2014 Feb; 20(2 Spec No.):E10. PubMed ID: 25764581
[No Abstract] [Full Text] [Related]
18. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in
Ferrucci PF; Di Giacomo AM; Del Vecchio M; Atkinson V; Schmidt H; Schachter J; Queirolo P; Long GV; Stephens R; Svane IM; Lotem M; Abu-Amna M; Gasal E; Ghori R; Diede SJ; Croydon ES; Ribas A; Ascierto PA;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361337
[TBL] [Abstract][Full Text] [Related]
19. Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib.
Scarfì F; Melotti B; Veronesi G; Ravaioli GM; Baraldi C; Lambertini M; Patrizi A; Dika E
Australas J Dermatol; 2019 Aug; 60(3):e242-e243. PubMed ID: 30724336
[No Abstract] [Full Text] [Related]
20. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.
Zaloum A; Falet JR; Elkrief A; Chalk C
Neurology; 2020 Feb; 94(7):322-323. PubMed ID: 31888971
[No Abstract] [Full Text] [Related]
[Next] [New Search]
